Metraipolis › archive › dc_7562353fc0be
Functional assays to screen and select monoclonal antibodies that target Yersinia pestis — Europe PMC PMID:37289480
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37289480
- DOI
- 10.1080/21645515.2023.2216085
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:59:35.301Z
- SHA-256 of the archived text
3f8255a3cf693fb94f854caeb7b73f0f9f5aad4fe26214dce0bd16a35e094cde- Stable URL of this page
https://metraipolis.com/documento/dc_7562353fc0be
How to cite
Functional assays to screen and select monoclonal antibodies that target Yersinia pestis — Europe PMC PMID:37289480 — Europe PMC (en), https://europepmc.org/article/MED/37289480 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7562353fc0be (Metraipolis archive dc_7562353fc0be, sha256 3f8255a3cf693fb94f854caeb7b73f0f9f5aad4fe26214dce0bd16a35e094cde)
BibTeX
@misc{dc7562353fc0be,
title = {Functional assays to screen and select monoclonal antibodies that target Yersinia pestis — Europe PMC PMID:37289480},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37289480},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7562353fc0be; sha256 3f8255a3cf693fb94f854caeb7b73f0f9f5aad4fe26214dce0bd16a35e094cde},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37289480. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Yersinia pestis is a gram-negative bacterium that causes plague in animals and humans. Depending on the route of disease transmission, the bacterium can cause an acute, often fatal disease that has a narrow window for treatment with antibiotics. Additionally, antibiotic resistant strains have been identified, emphasizing the need for novel treatments. Antibody therapy is an appealing option that can direct the immune system to clear bacterial infections. Advances in biotechnology have made both engineering and producing antibodies easier and more affordable. In this study, two screening assays were optimized to evaluate the ability of antibodies to promote phagocytosis of Y. pestis by macrophages and to induce a cytokine signature in vitro that may be predictive of protection in vivo. We evaluated a panel of 21 mouse monoclonal antibodies targeting either the anti-phagocytic capsule F1 protein or the LcrV antigen, which is part of the type 3 secretion system that facilitates translocation of virulence factors into the host cell, using two functional assays. Anti-F1 and anti-LcrV monoclonal antibodies both increased bacterial uptake by macrophages, with greater uptake observed in the presence of antibodies that were protective in the mouse pneumonic plague model. In addition, the protective anti-F1 and anti-LcrV antibodies produced unique cytokine signatures that were also associated with in vivo protection. These antibody-dependent characteristics from in vitro functional assays will be useful in down-selecting efficacious novel antibodies that can be used for treatment of plague. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Human vaccines & immunotherapeutics, 2023 (prima pubblicazione 2023-06-08). Identificativi: PMID 37289480 · PMCID PMC10332183 · DOI 10.1080/21645515.2023.2216085. Parole chiave degli autori: Mice; Yersinia pestis; Immunity; plague; Antibody Screening; Antibody Treatment. Descrittori MeSH principali: Yersinia pestis; Plague; Plague Vaccine. Pagina: https://europepmc.org/article/MED/37289480 — https://doi.org/10.1080/21645515.2023.2216085. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T12:29:42.088Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.